Answers are grounded in this paper and cite their sources.
Preclinical study reveals that anti-TLR3 treatment lowers blood pressure and arterial constriction in hypertensive rats, indicating a novel therapeutic target.
BACKGROUND: Toll-like receptors (TLRs) are implicated in blood pressure (BP) regulation, but the role of TLR3 in hypertension remains poorly understood. We hypothesized that anti-TLR3 treatment reduces vasoconstriction and lowers BP in hypertension. METHODS: To test this, spontaneously hypertensive rats (SHR) and normotensive Wistar controls were treated with either IgG or an anti-TLR3 antibody. BP was measured, and mesenteric arteries were assessed for vascular reactivity, protein expression, and histology. RESULTS: Anti-TLR3 treatment significantly reduced BP in SHR. It also decreased the contractile response to noradrenaline, an effect abolished by indomethacin, and prevented the increased COX-1 expression in SHR while reducing COX-2 expression in both strains. Furthermore, anti-TLR3 reduced collagen I and increased collagen III deposition in the mesenteric artery and lowered TLR3 expression in the tunica media of SHR. CONCLUSION: These findings support TLR3 may represent a novel therapeutic target in hypertension.
No takes yet. Share an insight, caveat, or question.
Santana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: